Introduction
============

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are widely used by patients with acute pain or with chronic pain due to osteoarthritis (OA) and rheumatoid arthritis (RA) (ACR Recommendations 2000; [@b20]; [@b22]; [@b36]). They put them at increased risk for clinically important damage to the mucosa of the upper part of the gastrointestinal tract ([@b44]), with a relative risk (RR) of 2.7--5.4 for the so-called PUBs and POBs (PUBs: Perforation, clinically manifest Ulcer and Bleeding; POBs: Perforation, Obstruction, Bleeding) ([@b19]; [@b32]). OA and RA patients were found to be 2.5--5.5 times more hospitalized for NSAID-related gastro-intestinal (GI) events than the general population ([@b38]) and 5%--10% of PUBs are fatal ([@b3]).

Cyclo-oxygenase 2 (COX2)-selective inhibitors have been developed based on the finding that the COXs that are constitutively involved in the physiology of the GI mucosa (COX1) are different from the ones that are inducible by inflammation (COX2) ([@b41]; [@b43]; [@b14]). Therefore, selective inhibition of COX2 could dissociate anti-inflammatory activity from GI side effects. In this way, COX2 selective inhibitors should reduce clinically manifest ulcers and ulcer complications compared with non-selective NSAIDs, meanwhile exerting similar effects on acute pain (eg, primary dysmenorrhea and following orthopedic or dental surgery) and chronic pain in patients with OA or RA.

Preclinical in vitro and animal studies using have been performed proving that COX2 selectivity is a promising approach ([@b41]; [@b43]; [@b14]). Several endoscopic studies with selective COX2 inhibitors in humans have shown a reduction of the occurrence of upper GI lesions compared to non-selective NSAIDs ([@b21]); moreover, it has been shown that the endoscopic ulcer rate in healthy volunteers or in patients with osteoarthritis was not different between COX2 inhibitor-users and placebo ([@b27]; [@b33]).

However, endoscopic lesions have been considered only as an indicator and surrogate endpoint for clinical upper GI safety ([@b16]). Therefore, clinical trials have been performed to study the effect of selective COX2 inhibitors on clinical relevant upper GI events. Since clinically manifest ulcers and ulcer complications are relatively scarce, very large studies (with a high number of patients) have been performed to show differences in PUBs and POBs.

During the course of emerging studies, it became clear that selective COX2 inhibitors could be associated with an increased incidence of cardiovascular (CV) thrombotic events, including stroke and particularly myocardial infarction (MI), as demonstrated in the VIGOR study, in which the risk of MI was higher in RA-patients treated with rofecoxib than in naproxen users ([@b5]). At that time, it was debated whether this difference in CV risk was the result of a protective effect of naproxen on the incidence of MI ([@b5]), or a consequence (side-effect) of the use of COX2 inhibitors.

Later on, in studies developed to observe whether the use of COX2 inhibitors protected against the occurrence of colonic polyps, it has become clear that rofecoxib, as compared to placebo, doubles the risk for thrombotic events, mainly myocardial infarction and ischemic CV events ([@b6]; [@b24]). Also for other COX2 inhibitors, celecoxib and valdecoxib, an elevated CV risk has been shown ([@b31]; [@b40]).

Although the exact mechanism of this association is still unclear, the balance between prostacyclin (PGI2) and thromboxane A~2~ (TXA~2~) is presumably shifted to an increased risk for thrombo-embolic events ([@b14]). It has been suggested that COX2 is up regulated in vascular segments under conditions of increased vascular shear stress, and that the reduction of endovascular production of prostacyclin by the use of COX2 inhibitors induces an elevated risk of vascular thrombotic events ([@b39]).

Besides an elevated CV risk, it has recently been shown that the use of conventional NSAIDs is associated with edema, congestive heart failure, cardiac arrhythmias, and an increased risk of CV events ([@b23]; [@b30]; [@b42]; [@b45]).

In this context, it was realised that the development of new selective COX2 inhibitors had to be evaluated in a much broader context of safety than only GI protection and had to include data on CV safety ([@b37]; [@b13]; [@b35]; [@b8]; [@b26]). In order to perform such studies, larger trials were needed with more endpoints than in the original studies that focused on GI protection only. In addition, also for the non-selective NSAIDs additional data were required to adequately judge their effect on CV risk.

Several clinical trials have been performed to study both the GI and CV safety with COX2 ([Tables 1](#tbl1){ref-type="table"}--[4](#tbl4){ref-type="table"}), including VIGOR (rofecoxib vs naproxen) ([@b5]), CLASS (celecoxib vs diclofenac and ibuprofen) ([@b37]), MEDAL (etoricoxib vs diclofenac in a pooled analysis) ([@b8]; [@b26]), and TARGET (lumiracoxib vs ibuprofen and naproxen) ([@b13]; [@b35]), which will be discussed in detail later in this review.

###### 

General description of main large-scale safety trials with selective COX2 inhibitors and description of patients excluded from participating in the studies

  Drug (reference)               Study    Diagnoses and patients (n)   Duration (months)   Comparator drug          Risk patients excluded GI history                           CV history
  ------------------------------ -------- ---------------------------- ------------------- ------------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Rofecoxib ([@b5])              VIGOR    RA (8 076)                   12                  Naproxen                 GI surgery, current B, IBD, previous or current PPI         History of CV last 2 yrs, MI or coronary bypass last yr, previous or current aspirin
  Celecoxib ([@b37])             CLASS    OA, RA (8 059)               6                   Ibuprofen, diclofenacv   Active GI, U last 30 d, any GI surgery                      No exclusion criteria
  Etoricoxib ([@b8]; [@b26])     MEDAL    OA, RA (37 701)              36                  Diclofenac               No exclusion PPI or misoprostol recommended if at GI risk   MI or coronary bypass or percutaneous coronary intervention during last 6 mo, aspirin recommended if at CV risk
  Lumiracoxib ([@b35]; [@b13])   TARGET   OA (18 325)                  12                  Ibuprofen, naproxen      On GI protection, U last 3 mo, B last yr, any P or O        MI (clinical, on ECG), stroke, coronary bypass graft surgery, new angina during last 6 mo, high CV risk without aspirin, severe heart failure, on anticoagulation therapy

**Abbreviations:** B, bleeding; CV, cardiovascular; GI, gastrointestinal; IBD, infl ammatory bowel disease; MI, myocardial infarction; O, obstruction; OA, osteoarthritis; P, perforation; RA, rheumatoid arthritis; PPI, proton pump inhibitors; U, ulcer.

###### 

Gastrointestinal endpoints in studies of selective COX2 inhibitors

  Drug (reference)               Study    GI protection allowed in study   GI endpoints                                                                     Hazard ratios, relative risks (RR) or incidence (%) of upper GI risk endpoints                           
  ------------------------------ -------- -------------------------------- ------------------------------------------------------ ------------------------- -------------------------------------------------------------------------------- ----------------------- -------------------
  Rofecoxib ([@b5])              VIGOR    Yes                              Confirmed POBU                                                                   0.5 (0.3--0.6)v                                                                  Idem                    Excluded
                                                                           Complicated GI (POB)                                                             0.4 (0.2--0.8)                                                                   Idem                    Excluded
  Celecoxib ([@b37])             CLASS    No                               POB                                                                              RR: 0.53 (0.26--1.11)                                                            RR: 0.35 (0.14--0.98)   1.0% vs 2.1, NS
                                                                           Symptomatic U + POB                                                              RR: 0.59 (0.38--0.94)                                                            RR: 0.48 (0.28--0.89)   4.7% vs 6.0%, NS
  Etoricoxib ([@b8]; [@b26])     MEDAL    Yes                              Clinical POBU[a](#tf2-1){ref-type="table-fn"}          All                       0.69 (0.57--0.83)                                                                0.60 (0.45--0.80)       0.78 (0.60--1.01)
                                                                                                                                  No PPI                    0.62 (0.45--0.83)                                                                0.60 (0.43--0.86)       0.93 (0.65--1.35)
                                                                                                                                  \+ PPI                    0.74 (0.58--0.95)                                                                0.59 (0.36--0.98)       0.64 (0.44--0.93)
                                                                           Complicated GI (POB)[a](#tf2-1){ref-type="table-fn"}   All                       0.91 (0.67--1.24)                                                                0.90 (0.53--1.50)       0.93 (0.63--1.36)
                                                                                                                                  No PPI                    1.03 (0.70--1.52)                                                                0.96 (0.52--1.79)       1.09 (0.66--1.77)
                                                                                                                                  \+ PPI                    0.72 (0.42--1.22)                                                                0.77 (0.30--1.95)       0.70 (0.37--1.34)
                                                                           Uncomplicated U[a](#tf2-1){ref-type="table-fn"}        All                       0.57 (0.45--0.74)                                                                0.50 (0.35--0.71)       0.67 (0.47--0.96)
                                                                                                                                  No PPI                    0.58 (0.41--0.81)                                                                0.49 (0.32--0.75)       0.77 (0.44--1.34)
                                                                                                                                  \+ PPI                    0.57 (0.39--0.83)                                                                0.53 (0.29--0.98)       0.61 (0.38--0.97)
  Lumiracoxib ([@b35]; [@b13])   TARGET   No                               Definite or probable complicated U (POB)                                                                                                                                                  
                                                                                                                                  vs ibuprofen + naproxen   0.34 (0.22--0.52)                                                                0.21 (0.12--0.37)       0.79 (0.40--1.55)
                                                                                                                                  vs ibuprofen              0.29 (0.14--0.59)                                                                0.17 (0.07--0.45)       0.92 (0.27--3.20)
                                                                                                                                  vs naproxen               0.37 (0.22--0.63)                                                                0.24 (0.12--0.50)       0.73 (0.32--1.65)

No treatment-by-subgroup interaction.

**Abbreviations:** B, bleeding; GI, gastrointestinal; O, obstruction; P, perforation; PPI, proton pump inhibitors; U, ulcer.

###### 

Cardiovascular endpoints in studies of selective COX2 inhibitors

  Drug (reference)               Study    Aspirin allowed   CV endpoints                                                                                               Hazard ratios or incidence of CV endpoints                                                            
  ------------------------------ -------- ----------------- ---------------------------------------------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ----------------------------------------------------
  Rofecoxib ([@b5])              VIGOR    No                MI                                                                                                         4.25 (1.39−17.37)                                  Idem                                               Excluded
                                                            CV death                                                                                                   [c](#tf3-3){ref-type="table-fn"}0.2% vs 0.2%, NS   Idem                                               Excluded
  Celecoxib ([@b37])             CLASS    Yes               MI, stroke or angina                                                                                       0.9% vs 1.0%, NS                                   0.5% vs 0.4%, NS                                   nr
  Etoricoxib ([@b8]; [@b26])     MEDAL    Stimulated        [a](#tf3-2){ref-type="table-fn"}Any thrombotic events                                                      0.95 (0.81−1.11)                                   [d](#tf3-4){ref-type="table-fn"}1.0% vs 1.0%, NS   [d](#tf3-4){ref-type="table-fn"}1.67% vs 1.87%, NS
                                                            [a](#tf3-2){ref-type="table-fn"}Arterial thrombotic events                                                 0.96 (0.81−1.13)                                   nr                                                 nr
                                                            [a](#tf3-1){ref-type="table-fn"},[b](#tf3-1){ref-type="table-fn"}APTC (all MI, stroke or vascular death)   0.96 (0.79−1.16)                                   nr                                                 nr
  Lumiracoxib ([@b35]; [@b13])   TARGET   Yes               [b](#tf3-2){ref-type="table-fn"}APTC (all MI, stroke or vascular death)                                                                                                                                          
                                                             vs ibuprofen + naproxen                                                                                   1.14 (0.78--1.66)                                  1.22 (0.74--2.02)                                  1.04 (0.59--1.84)
                                                             vs ibuprofen                                                                                              0.76 (0.41--1.40)                                  0.94 (0.44--2.04)                                  0.56 (0.20--1.54)
                                                             vs naproxen                                                                                               1.46 (0.89--2.37)                                  1.49 (0.76--2.92)                                  1.42 (0.70--2.90)
                                                            Confirmed or probable MI (clinical and silent)                                                                                                                                                                   
                                                             vs ibuprofen + naproxen                                                                                   1.31 (0.70--2.45)                                  1.47 (0.63--3.39)                                  1.14 (0.44--2.95)
                                                             vs ibuprofen                                                                                              0.66 (0.21--2.09)                                  0.75 (0.20--2.79)                                  0.47 (0.04--5.14)
                                                             vs naproxen                                                                                               1.77 (0.82--3.84)                                  2.37 (0.74--7.55)                                  1.36 (0.47--3.93)

Per-protocol analysis, similar results after ITT analysis.

APTC, Anti-Platelet Trialists\' Collaboration endpoint.

incidence.

events per 100 patient yrs.

**Abbreviations:** nr, not reported.

###### 

Incidence of other side effects in studies of selective COX2 inhibitors

  Study (reference)         Drugs                 Side effects Renal                           Edema                                                      Blood pressure                            Hypertension                              CHF                                              Hepatic ALT+AST+                                                    Cutaneous reactions                          
  ------------------------- --------------------- -------------------------------------------- ---------------------------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------------ ------------------ ------------------------------------------------ -------------------------------------------- ---------------------------------------
  VIGOR ([@b5])             Rofecoxib             1.2%                                         nr                                                         nr                                        nr                                        nr                                               nr                                                                  nr                                           nr
                            Naproxen              0.9%                                                                                                                                                                                                                                                                                                                                                          
  CLASS ([@b37])            Celecoxib             0.7%[\*](#tf4-1){ref-type="table-fn"}        2.8%                                                       nr                                        nr                                        1.7%[\*](#tf4-1){ref-type="table-fn"}            nr                 0.6%[\*](#tf4-1){ref-type="table-fn"}                                                         7.5%[\*](#tf4-1){ref-type="table-fn"}
                            Diclofenac            1.2%                                         3.5%                                                                                                                                           2.3%                                                                2.3%                                                                                          4.1%
  MEDAL ([@b8]; [@b26])     Etoricoxib            0.4%--2.3%                                   0.8%--1.9% ([\*\*](#tf4-3){ref-type="table-fn"}at 90 mg)   nr                                        nr                                        2.2%--2.5% [\*\*](#tf4-3){ref-type="table-fn"}   0.1%--0.7%         0.3%--0.4% [\*\*](#tf4-3){ref-type="table-fn"}                                                nr
                            Diclofenac            0.4 to 1.8%                                  0.4%--0.8%                                                                                                                                     0.7%--1.6%                                       0.1%--0.3%         1.5%--5.0%                                                                                    
  TARGET ([@b35]; [@b13])   Lumiracoxib           [\*\*\*](#tf4-4){ref-type="table-fn"}0.51%   nr                                                         +0.4 mm[§](#tf4-2){ref-type="table-fn"}   −0.1 mm[§](#tf4-2){ref-type="table-fn"}   nr                                               0.24%              0.07%[\$\$](#tf4-5){ref-type="table-fn"}         2.57%[\$\$\$](#tf4-5){ref-type="table-fn"}   nr
                            Naproxen/Diclofenac   0.37%                                                                                                   +2.1 mm                                   +0.5 mm                                                                                    0.34%              0.03%                                            0.63%                                        

p \< 0.05,

p \< 0.0001 vs control drug.

p \< 0.05 for discontinuations between treatment groups.

major renal events, NS.

serious liver abnormalities (not further specified), NS.

transaminases \>× 3 times upper normal limit, p \< 0.0001.

**Abbreviations:** ALT+, elevated alanine aminotransferase; AST+, elevated aspartate aminotransferase; CHF, cardiac heart failure; nr, not reported.

These studies differed between each other in many aspects. Differences included indications for treatment (OA and/or RA), number of patients included (between 8059 and 37,701), the comparator non-selective NSAIDs (naproxen, diclofenac, ibuprofen; none was placebo-controlled), duration of the study (6--36 months), exclusion or not because of history of GI risks/events (GI surgery, current bleeding, active GI disorder, recent ulcer, intake of GI protectors, bleeding last year, any perforation, obstruction or not), GI protection during the study (not allowed, allowed, stimulated in high risk patients), definitions of upper GI side effect endpoints (various combinations of PUBOs, eventually further specified as complicated or not), exclusion or not because of history of CV risks/events (during variable time periods before the study (during last 6 months to ever), and defined as any CV event or specified as MI (clinical or on ECG), coronary bypass, percutaneous coronary intervention, stroke, new angina, low dose aspirin (allowed, stimulated, or not allowed), severe heart failure), and definitions of CV side effect endpoints (MI alone, composite endpoints including variable combinations of MI, stroke, angina, any or arterial thrombotic events, or including more standardized outcomes from the Anti-Platelet Trialists' Collaboration endpoint).

In these studies, rofecoxib and etoricoxib decreased the risk of GI event endpoints ([Table 2](#tbl2){ref-type="table"}), but the size and significance of effects according to definitions of GI events and reporting on significance of interaction of treatment-by-subgroup analysis differed between the drugs ([@b5]; [@b37]; [@b8]; [@b26]). Celecoxib did not decrease the primary GI endpointv (POBs) over the entire duration of the study, but significantly reduced the risk of GI events when symptomatic ulcers were included in the analysis ([@b37]).

In these studies, rofecoxib increased the risk of MI (HR: 4.25, CI: 1.39--17.37) ([@b5]), which was the reason for withdrawal of rofecoxib (Vioxx^®^) from the market in September 2004. Low dose celecoxib and etoricoxib did not affect the risk of pre-specified composite CV endpoints in the total group of patients and in specified subgroups (on low dose aspirin or not) as compared to their comparator non-selective NSAID(s) ([Table 3](#tbl3){ref-type="table"}) ([@b37]; [@b8]; [@b26]).

It is important to realize that the similarity of incidence of CV risk between selective and non-selective COX inhibitors does not mean that there is no increased CV risk of selective COX2 inhibitors compared to placebo. On the contrary, compared to placebo, it has been demonstrated that the selective COX2 inhibitors rofecoxib ([@b6]; [@b24]) and celecoxib ([@b40]) at high doses increase the risk of CV events compared to placebo. Furthermore, non-selective NSAIDs, such as ibuprofen ([@b2]), diclofenac ([@b2]), but probably not naproxen ([@b2]) and even paracetamol ([@b9]), were associated with an increased risk for CV events compared to placebo in meta-analyses.

In this complex safety context, we review here the data on the effects and safety of lumiracoxib, a highly selective COX2 inhibitor.

Lumiracoxib
===========

Preclinical data
----------------

Lumiracoxib (Prexige^®^) is a selective COX2 inhibitor developed for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain ([@b28]; [@b11]).

Lumiracoxib differs structurally from other drugs in the class of selective COX2 inhibitors ([@b7]; [@b29]). The other inhibitors contain a tricyclic ring and a sulfone or sulfonamide group ([@b7]) whereas lumiracoxib is a phenyl acetic acid derivative. It has the highest selectivity (selective for COX2 compared with COX1 in the human whole blood assay with a ratio of 515:1 in healthy subjects and in patients with osteoarthritis or rheumatoid arthritis) and a fairly short plasma half-life (3--6 hours) compared with other COX2-selective inhibitors ([@b11]).

Lumiracoxib has good oral bioavailability (74%). It is rapidly absorbed, reaching maximum plasma concentrations 2 hours after dosing, and is highly plasma protein bound. Lumiracoxib has a short elimination half-life from plasma (mean 4 hours) and demonstrates dose-proportional plasma pharmacokinetics with no accumulation during multiple dosing.

Lumiracoxib is metabolized extensively prior to excretion, with only a small amount excreted unchanged in urine or feces. Lumiracoxib and its metabolites are excreted via renal and fecal routes in approximately equal amounts ([@b28]).

Lumiracoxib does not exhibit any clinically meaningful interactions with a range of commonly used medications including aspirin (acetylsalicylic acid), fluconazole, an ethinylestradiol- and levonorgestrel-containing oral contraceptive, omeprazole, the antacid Maalox^®^, methotrexate, and warfarin (although, as in common practice, routine monitoring of coagulation is recommended when lumiracoxib is co-administered with warfarin) ([@b28]).

Clinical efficacy
-----------------

The effectiveness of lumiracoxib was superior to placebo in patients with OA at doses of 100 mg and 200 mg once daily and similar to celecoxib and non-selective NSAID, as described and reviewed in detail in [@b28].

Several studies have been shown the superiority of lumiracoxib compared to placebo in pain in RA ([@b15]), after surgery, orthopedic surgery, primary dysmenorrhea and tension headache ([@b28]).

Safety
------

### Upper gastrointestinal safety: endoscopic studies

In endoscopic studies, lumiracoxib has been associated with a rate of acute gastric injury and chronic ulcer formation that does not differ from placebo ([@b34]) and which was significantly lower than with the non-selective NSAID ibuprofen and with celecoxib ([@b18]; [@b25]).

### Clinical gastrointestinal safety

To establish the gastrointestinal safety of lumiracoxib, the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) was performed to test the hypothesis that patients with osteoarthritis, randomized to lumiracoxib (400 mg once daily, which is 2--4 times the recommended dose for osteoarthritis), had significantly fewer complicated ulcers than patients randomized to either ibuprofen (3 × 800 mg/day) or naproxen (2 × 500 mg/day), without affecting CV risk ([@b13]; [@b35]). To address these issues, TARGET (n =18,325) was, by design, much larger than CLASS (n =8059) and VIGOR (n =8 076) outcome trials, but smaller than the pooled analysis in MEDAL (n = 37,701).

The TARGET trial included patients with clinical OA of hip, knee or hands, or with radiographic OA of the spine (without of radicular symptoms). Based on the GI risk profile at baseline, patients were excluded if they were on GI protection, had an upper GI ulcer during the last 3 months, GI bleeding last year or any history of perforation or obstruction ([Table 1](#tbl1){ref-type="table"}) ([@b35]). Lumiracoxib showed, in the total group, a 3- to 4-fold reduction in upper GI ulcer complications (POBs) compared both comparators combined (RR: 0.34, CI: 0.22--0.52) and either naproxen or ibuprofen ([Table 2](#tbl2){ref-type="table"}). Remarkably, the relative risk reduction for lumiracoxib (0.34) seems at first sight to be larger than for rofecoxib, celecoxib, and etoricoxib. However, this comparison is difficult, if not impossible to interpret, since it is not based on a head to head comparison, and the inclusion and exclusion criteria and definition of endpoints of these studies were different. This effect was found in patients not taking low dose aspirin (RR: 0.21, CI: 0.12--0.37), but was not significant in those taking low dose aspirin (RR: 0.79, CI: 0.40--1.55).

### Clinical cardiovascular safety

Based on CV risk profile at baseline, patients were excluded from the TARGET study if they had a history of MI (clinical or silent as shown on ECG), stroke, coronary bypass, new angina of recent onset (last 6 months), high CV risk without intake of aspirin or severe heart failure ([@b13]). The primary composite endpoint (the incidence of MI, stroke, and CV death) did not differ between lumiracoxib and ibuprofen or naproxen combined (RR: 1.14, CI: 0.78--1.66) or separately, irrespective of aspirin use (RR: 1.22 and 1.04). Thus, the overall CV signal showed no difference but this is because the study is underpowered to demonstrate statistically significant and clinically meaningful differences. There was a trend towards more CV events relative to naproxen (RR: 1.46, CI: 0.89--2.37) and fewer events relative to ibuprofen (RR: 0.76, CI: 0.41--1.40).

It is important to realize that the TARGET trial has been performed in patients with a relatively low risk for CV events. Patients were excluded from the study if they had a MI, stroke, coronary artery bypass graft surgery, percutaneous coronary intervention or new-onset angina within 6 months prior to screening, electrocardiogram (ECG) evidence of silent myocardial ischemia, New York Heart Association congestive heart failure class III--IV, or if they were receiving anticoagulation therapy. As a consequence, it cannot be fully excluded that a difference between the comparators would have been observed if more high risk patients would have been enrolled.

The incidence of composite GI and CV endpoints combined fell by 35% in patients treated with lumiracoxib compared to both comparators (RR: 0.65, CI: 0.49--0.84), by 50% compared to ibuprofen (p \< 0.01) and by 25% compared to naproxen (NS).

### Other safety data

Non-selective NSAIDs interfere with COX1 and COX2 in the kidney ([@b17]). Their most common renal side effect is peripheral edema due to increased sodium retention ([@b17]), which also is one of the contributors to an increase in blood pressure. Acute renal failure is a rare but potentially serious complication of non-selective NSAIDs ([@b17]), which predominantly occurs in elderly with cardiovascular involvement during periods of dehydration (diarrhea, high fever). Also selective COX2 inhibitors may cause edema, congestive heart failure and modest elevations of blood pressure ([@b17]). In the MEDAL study, more discontinuations were observed in etoricoxib users due to hypertension and edema than in diclofenac users (no difference was found for congestive heart failure) ([@b8]; [@b26]).

In the TARGET study ([@b13]; [@b35]), the incidence of major renal events and chronic heart failure were similar between the treatment groups ([Table 4](#tbl4){ref-type="table"}), while unfortunately the incidence of peripheral edema was not reported. Interestingly, blood pressure remained stable in patients treated with lumiracoxib, which was significantly different from the moderate but significant increase in blood pressure with naproxen and diclofenac. In the TARGET study no data were presented on cutaneous side effects ([@b13]; [@b35]).

Hepatotoxicity has been the reason for withdrawal of some NSAIDs from the market, but symptomatic hepatic effects attributable to NSAIDs are rare and usually mild ([@b4]). Lumiracoxib has a molecular phenyl acetic acid structure that is similar to that of diclofenac, the most widely prescribed NSAID world-wide, probably with an elevated risk for hepatotoxicity (which is estimated to occur in 4% of all patients). In the TARGET study the incidence of serious liver abnormalities (not further specified in the manuscript) was similar between the treatment groups, but lumiracoxib was associated with a RR of 3.97 (CI: 2.96--5.32) for increase in liver tests above 3 times the upper normal limit ([@b13]; [@b35]). Thus, the risk of hepatotoxicity with the use of lumiracoxib is higher than for naproxen and ibuprofen. At the time of first submission of this manuscript, lumiracoxib was withdrawn from the market in Australia (where it had been on the market for several years and prescribed to 60,000 patients in doses up to 400 mg/day) because of 8 reports of serious liver adverse reactions to the drug, including 2 deaths and 2 liver transplants, further details of which were not yet available. Meanwhile, due to these serious liver adverse affects at doses \>100 mg/day, lumiracoxib was withdrawn from the market in several countries, including the UK and Germany. In this context lumiracoxib should, were available, be limited to the lowest effective dose for the shortest possible duration of treatment. The reader is advised to inspect the safety issues that are emerging about liver safety, including baseline evaluation of history of liver diseases and regular checking liver function during treatment, and instructions about follow-up of liver function tests during treatment.

Conclusions
===========

Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in OA, with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper GI side effects in patients not taking aspirin and a similar incidence of CV side effects as compared to naproxen or ibuprofen.

In the context of earlier guidelines (ACR Recommendations 2000; [@b20]; [@b22]; [@b36]) and taking into account the GI and CV safety results of the TARGET study ([@b13]; [@b35]), lumiracoxib is *strictu sensu* indicated in the treatment of patients with clinical OA of hip, knee or hands, or with radiographic OA of the spine, who do not respond to conventional treatment (such as analgesics \[acetaminophen\], physical therapy, and weight reduction in case of hip and knee OA), who have a moderate or high GI risk (with the restriction that in the TARGET study patients with a recent ulcer or bleeding or any history of perforation or obstruction were excluded) and a low CV risk and are not taking low dose aspirin ([Table 5](#tbl5){ref-type="table"}) ([@b10]).

###### 

Proposed indications for the use of selective COX2 and non-selective NSAIDs according to GI and CV risk ([@b10])

  CV risk                                GI risk[a](#tf5-1){ref-type="table-fn"}                                                                                   
  -------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ -----------------------------------------------------------------
  Low                                    NSAID                                                        NSAID + PPI/misoprostol or COX2 inhibitor                    COX2 inhibitor + PPI
  High[b](#tf5-2){ref-type="table-fn"}   NSAID[c](#tf5-3){ref-type="table-fn"} + PPI or misoprostol   NSAID[c](#tf5-3){ref-type="table-fn"} + PPI or misoprostol   Avoid NSAIDs or COX2 inhibitord[d](#tf5-4){ref-type="table-fn"}

Gastrointestinal risk is arbitrarily defi ned as low (no risk factors), moderate (presence one or two risk factors), or high (more than two risk factors, previous ulcer complications, or concomitant use of corticosteroids or anticoagulants). All patients with a history of ulcers who require NSAIDs should be tested for *H. pylori* and if infection is present, eradication therapy should be given.

High cardiovascular risk is arbitrarily defi ned as the requirement for low-dose aspirin for primary cardiovascular event prevention (calculated 10-year cardiovascular risk \>10%) or secondary prevention of serious cardiovascular events.

cNaproxen is the preferred NSAID in patients with a high cardiovascular risk.

Ibuprofen should be avoided with aspirin ([@b12]).

**Abbreviations:** PPI, proton pump inhibitors.

Lumiracoxib has been secured EMEA approval under the name of Prexige™ and Prexigen™ and has been launched in the UK since January 2006, where it is indicated for symptomatic treatment of osteoarthritis as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery (www.emea.eu). The UK acted as the reference state in the EU's mutual recognition procedure.

In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, the prescription and use of COX2 inhibitors should be based on the risk and safety profile of the patient. One example is given in [Table 5](#tbl5){ref-type="table"}, in which the use of selective COX2 is proposed to be limited to patients with a low CV risk together with a moderate or high GI risk ([@b10]). In addition, there is further need for long-term GI and CV safety studies on the use of selective and non-selective COX inhibitors. In view of the liver adverse effects, lumiracoxib should be limited to the lowest effective dose for the shortest possible duration of treatment, with special attention for liver toxicity according to the upcoming safety instructions. However, at the time of submission, lumiracoxib had been withdrawn from the market in several countries, including the UK and Germany, because of liver side effects at doses \>100 mg/day. Meanwhile, at the time of proof approval of this paper, the European Medicines Agency (EMEA) had completed a review of the safety of medicines containing lumiracoxib. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines no longer outweigh their risks, and that all marketing authorizations should be withdrawn throughout Europe because of the risk of serious side effects affecting the liver ([www.emea.europa.eu](www.emea.europa.eu)).
